4-[6-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-pyrimidin-2-ylamine, 95.0%, 1g

(4-(N-Cyclohexylsulfamoyl)phenyl)boronic acid, 97%, 1g

2-(5-methyl-3-(thiophen-2-yl)-1H-pyrazol-1-yl)ethan-1-amine, 95.0%, 250mg

Long working distance plan phase contrast Fluarex 40x/0.65 infinity corrected IOS objective, corrected for 1 mm petri dish thickness

1-(Dimethoxymethyl)-4-methoxybenzene, 95.0%, 1g

(2,3-Dihydro-1H-inden-2-yl)methanol, 95.0%, 5g

6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-9H-purine, 95.0%, 250mg

9-Anthracenemethanol, 98.0%, 10g

Benzoylacetonitrile, 98.0%, 10g

2-Phenoxyethylamine>98.0%(GC)5g

3-DEAZAADENOSINE, 1mg

Dodecyl isocyanate, 97.0%, 250mg

2-(Bis(3,5-di-tert-butylphenyl)phosphino)-N-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)benzamide, 100mg